Skip to main content
Top
Published in: Psychiatric Quarterly 1/2019

01-03-2019 | Original Paper

Correlations between Body Mass Index, Plasma High-Sensitivity C-Reactive Protein and Lipids in Patients with Schizophrenia

Authors: Ted Boozalis, Sridevi Devaraj, Olaoluwa O. Okusaga

Published in: Psychiatric Quarterly | Issue 1/2019

Login to get access

Abstract

High prevalence of obesity in individuals with schizophrenia, associated with metabolic syndrome, leads to high rate of premature deaths from cardiovascular disease (CVD) in this population. Body mass index (BMI) and C-reactive protein (CRP) are correlated in the general population but this relationship has not been fully elucidated in patients with schizophrenia. We aimed to evaluate the correlation between BMI and CRP while relating both variables to plasma lipids in patients with schizophrenia. BMI, fasting high sensitivity CRP (hs-CRP), cotinine, and lipids were measured in 106 patients with schizophrenia (diagnosis confirmed with MINI). Pearson’s and partial correlations (adjusting for age, sex, race, education and cotinine) between BMI, hs-CRP and lipids were calculated. Based on BMI, the patients were divided into normal-weight vs. overweight/obese and t-tests and linear regression were done to compare hs-CRP and lipids in the 2 groups. BMI positively correlated with hs-CRP (r = 0.29, p = 0.004). BMI and hs-CRP negatively correlated with HDL in the total sample (r = −0.29, p = 0.004; r = −0.37, p < 0.001 respectively). Furthermore, hs-CRP negatively correlated with HDL in overweight/obese patients (r = −0.41, p = 0.003), but not in normal-weight patients. hs-CRP and triglycerides were higher (1.62 ± 0.09 mg/L vs. 0.56 ± 0.08 mg/L, p < 0.001; 121.77 ± 8.96 mg/dL vs. 91.23 ± 6.52 mg/dL, p = 0.008 respectively) and HDL lower (39.55 ± 1.48 mg/dL vs. 50.68 ± 2.24 mg/dL, p < 0.001) in overweight/obese patients. Being overweight/obese is associated with increased inflammation and dyslipidemia in patients with schizophrenia. Effective interventions to prevent weight gain in schizophrenia are urgently needed.
Literature
2.
go back to reference Na K-S, Jung H-Y, Kim Y-K. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:277–86.CrossRef Na K-S, Jung H-Y, Kim Y-K. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:277–86.CrossRef
3.
go back to reference Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol. 2011;14:997–1012.CrossRefPubMed Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol. 2011;14:997–1012.CrossRefPubMed
4.
go back to reference Cameron IM, Hamilton RJ, Fernie G, MacGillivray SA. Obesity in individuals with schizophrenia: a case controlled study in Scotland. BJPsych Open. 2017;3:254–6.CrossRefPubMedPubMedCentral Cameron IM, Hamilton RJ, Fernie G, MacGillivray SA. Obesity in individuals with schizophrenia: a case controlled study in Scotland. BJPsych Open. 2017;3:254–6.CrossRefPubMedPubMedCentral
5.
go back to reference Lopresti A, Drummond P. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;45:92–9.CrossRef Lopresti A, Drummond P. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;45:92–9.CrossRef
6.
go back to reference Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. World J Diabetes. 2017;8:390–396. Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. World J Diabetes. 2017;8:390–396.
7.
go back to reference Jakobsen AS, Speyer H, Norgaard HCB, Hjorthoj C, Krogh J, Mors O, et al. Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders - baseline and two-years findings from the CHANGE trial. Schizophr Res. 2018. https://doi.org/10.1016/j.schres.2018.02.047. Jakobsen AS, Speyer H, Norgaard HCB, Hjorthoj C, Krogh J, Mors O, et al. Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders - baseline and two-years findings from the CHANGE trial. Schizophr Res. 2018. https://​doi.​org/​10.​1016/​j.​schres.​2018.​02.​047.
8.
go back to reference Jeon SW, Kim YK. Unresolved issues for utilization of atypical antipsychotics in schizophrenia: Antipsychotic polypharmacy and metabolic syndrome. Int J Mol Sci. 2017;18:2174. Jeon SW, Kim YK. Unresolved issues for utilization of atypical antipsychotics in schizophrenia: Antipsychotic polypharmacy and metabolic syndrome. Int J Mol Sci. 2017;18:2174.
9.
go back to reference Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther. 2010;125:169–79.CrossRefPubMed Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther. 2010;125:169–79.CrossRefPubMed
11.
go back to reference Bruijnzeel D, Suryadevara U, Tandon R. Antipsychotic treatment of schizophrenia: an update. Asian J Psychiatr. 2014;11:3–7. Bruijnzeel D, Suryadevara U, Tandon R. Antipsychotic treatment of schizophrenia: an update. Asian J Psychiatr. 2014;11:3–7.
12.
go back to reference Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.CrossRefPubMed Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.CrossRefPubMed
13.
go back to reference Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, Müller DJ, Hahn MK. The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: A systematic review and implications for treatment. Front Neurosci. 2018;11:741. Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, Müller DJ, Hahn MK. The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: A systematic review and implications for treatment. Front Neurosci. 2018;11:741.
14.
go back to reference Steiner J, Bernstein H-G, Schiltz K, Muller UJ, Westphal S, Drexhage HA, et al. Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:287–94.CrossRef Steiner J, Bernstein H-G, Schiltz K, Muller UJ, Westphal S, Drexhage HA, et al. Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:287–94.CrossRef
15.
go back to reference Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 2004;65(Suppl 1):13–26.PubMed Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 2004;65(Suppl 1):13–26.PubMed
18.
go back to reference Chung K-H, Chen P-H, Kuo C-J, Tsai S-Y, Huang S-H, Wu W-C. Risk factors for early circulatory mortality in patients with schizophrenia. Psychiatry Res. 2018;267:7–11.CrossRefPubMed Chung K-H, Chen P-H, Kuo C-J, Tsai S-Y, Huang S-H, Wu W-C. Risk factors for early circulatory mortality in patients with schizophrenia. Psychiatry Res. 2018;267:7–11.CrossRefPubMed
19.
go back to reference Miller BJ, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses. 2014;7:223–30.CrossRefPubMed Miller BJ, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses. 2014;7:223–30.CrossRefPubMed
20.
go back to reference Ohaeri JU, Hedo CC, Lagundoye OO. The profile of C-reactive proteins in functional psychotic states in a cohort in Nigeria. Acta Psychiatr Scand. 1993;88:252–5.CrossRefPubMed Ohaeri JU, Hedo CC, Lagundoye OO. The profile of C-reactive proteins in functional psychotic states in a cohort in Nigeria. Acta Psychiatr Scand. 1993;88:252–5.CrossRefPubMed
21.
go back to reference Fernandes BS, Steiner J, Bernstein H-G, Dodd S, Pasco JA, Dean OM, et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry. 2016;21:554–64.CrossRefPubMed Fernandes BS, Steiner J, Bernstein H-G, Dodd S, Pasco JA, Dean OM, et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry. 2016;21:554–64.CrossRefPubMed
22.
go back to reference van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008;64:820–2.CrossRefPubMed van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008;64:820–2.CrossRefPubMed
23.
go back to reference Boozalis T, Teixeira AL, Cho RY-J, Okusaga O. C-reactive protein correlates with negative symptoms in patients with schizophrenia. Front Public Heal. 2018;5:360.CrossRef Boozalis T, Teixeira AL, Cho RY-J, Okusaga O. C-reactive protein correlates with negative symptoms in patients with schizophrenia. Front Public Heal. 2018;5:360.CrossRef
24.
go back to reference Misiak B, Stańczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: a systematic review. Schizophr Res. 2018;192:16–29.CrossRefPubMed Misiak B, Stańczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: a systematic review. Schizophr Res. 2018;192:16–29.CrossRefPubMed
25.
go back to reference Horsdal HT, Köhler-Forsberg O, Benros ME, Gasse C. C-reactive protein and white blood cell levels in schizophrenia, bipolar disorders and depression - associations with mortality and psychiatric outcomes: a population-based study. Eur Psychiatry. 2017;44:164–72.CrossRefPubMed Horsdal HT, Köhler-Forsberg O, Benros ME, Gasse C. C-reactive protein and white blood cell levels in schizophrenia, bipolar disorders and depression - associations with mortality and psychiatric outcomes: a population-based study. Eur Psychiatry. 2017;44:164–72.CrossRefPubMed
26.
go back to reference Barzilay R, Lobel T, Krivoy A, Shlosberg D, Weizman A, Katz N. Elevated C-reactive protein levels in schizophrenia inpatients is associated with aggressive behavior. Eur Psychiatry. 2016;31:8–12.CrossRefPubMed Barzilay R, Lobel T, Krivoy A, Shlosberg D, Weizman A, Katz N. Elevated C-reactive protein levels in schizophrenia inpatients is associated with aggressive behavior. Eur Psychiatry. 2016;31:8–12.CrossRefPubMed
27.
go back to reference Szortyka MFV, Cristiano VB, Ceresér KM, Francesconi LP, Lobato MI, Gama C, et al. Physical functional capacity and C-reactive protein in schizophrenia. Front Psych. 2016;7:131. Szortyka MFV, Cristiano VB, Ceresér KM, Francesconi LP, Lobato MI, Gama C, et al. Physical functional capacity and C-reactive protein in schizophrenia. Front Psych. 2016;7:131.
28.
go back to reference Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev. 2013;14:232–44.CrossRefPubMed Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev. 2013;14:232–44.CrossRefPubMed
29.
go back to reference Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.CrossRefPubMed Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.CrossRefPubMed
30.
go back to reference Firdous S. Correlation of CRP, fasting serum triglycerides and obesity as cardiovascular risk factors. J Coll Physicians Surg Pak. 2014;24:308–15.PubMed Firdous S. Correlation of CRP, fasting serum triglycerides and obesity as cardiovascular risk factors. J Coll Physicians Surg Pak. 2014;24:308–15.PubMed
31.
go back to reference Bonamichi BDSF, Lee J. Unusual suspects in the development of obesity-induced inflammation and insulin resistance: NK cells, iNKT cells, and ILCs. Diabetes Metab J. 2017;41:229–50.CrossRefPubMedPubMedCentral Bonamichi BDSF, Lee J. Unusual suspects in the development of obesity-induced inflammation and insulin resistance: NK cells, iNKT cells, and ILCs. Diabetes Metab J. 2017;41:229–50.CrossRefPubMedPubMedCentral
32.
go back to reference Gutierrez J, Alloubani A, Mari M, Alzaatreh M. Cardiovascular disease risk factors: Hypertension, diabetes mellitus and obesity among Tabuk Citizens in Saudi Arabia. Open Cardiovasc Med J. 2018;12:41–9. Gutierrez J, Alloubani A, Mari M, Alzaatreh M. Cardiovascular disease risk factors: Hypertension, diabetes mellitus and obesity among Tabuk Citizens in Saudi Arabia. Open Cardiovasc Med J. 2018;12:41–9.
33.
go back to reference Devaraj S, Valleggi S, Siegel D, Jialal I. Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atheroscler Rep. 2010;12:110–8.CrossRefPubMedPubMedCentral Devaraj S, Valleggi S, Siegel D, Jialal I. Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atheroscler Rep. 2010;12:110–8.CrossRefPubMedPubMedCentral
34.
go back to reference Rhainds D, Brodeur MR, Tardif J-C. Lipids, apolipoproteins and inflammatory biomarkers of cardiovascular risk. What have we learned? Clin Pharmacol Ther. 2018;104:244–56.CrossRefPubMed Rhainds D, Brodeur MR, Tardif J-C. Lipids, apolipoproteins and inflammatory biomarkers of cardiovascular risk. What have we learned? Clin Pharmacol Ther. 2018;104:244–56.CrossRefPubMed
35.
go back to reference Wang J, Tan G-J, Han L-N, Bai Y-Y, He M, Liu H-B. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017;14:135–50.PubMedPubMedCentral Wang J, Tan G-J, Han L-N, Bai Y-Y, He M, Liu H-B. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017;14:135–50.PubMedPubMedCentral
36.
go back to reference Abraham J, Campbell CY, Cheema A, Gluckman TJ, Blumenthal RS, Danyi P. C-reactive protein in cardiovascular risk assessment: a review of the evidence. J Cardiometab Syndr. 2007;2:119–23.CrossRefPubMed Abraham J, Campbell CY, Cheema A, Gluckman TJ, Blumenthal RS, Danyi P. C-reactive protein in cardiovascular risk assessment: a review of the evidence. J Cardiometab Syndr. 2007;2:119–23.CrossRefPubMed
37.
go back to reference Joseph J, Depp C, Martin AS, Daly RE, Glorioso DK, Palmer BW, et al. Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr Res. 2015;168:456–60.CrossRefPubMedPubMedCentral Joseph J, Depp C, Martin AS, Daly RE, Glorioso DK, Palmer BW, et al. Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr Res. 2015;168:456–60.CrossRefPubMedPubMedCentral
38.
go back to reference Dieset I, Hope S, Ueland T, Bjella T, Agartz I, Melle I, et al. Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. Schizophr Res. 2012;140:169–74.CrossRefPubMed Dieset I, Hope S, Ueland T, Bjella T, Agartz I, Melle I, et al. Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. Schizophr Res. 2012;140:169–74.CrossRefPubMed
39.
go back to reference Vuksan-Cusa B, Sagud M, Jakovljevic M, Peles AM, Jaksic N, Mihaljevic S, et al. Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia. Nord J Psychiatry. 2013;67:320–5.CrossRefPubMed Vuksan-Cusa B, Sagud M, Jakovljevic M, Peles AM, Jaksic N, Mihaljevic S, et al. Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia. Nord J Psychiatry. 2013;67:320–5.CrossRefPubMed
40.
go back to reference Fawzi MH, Fawzi MM, Fawzi MM, Said NS. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res. 2011;190:91–7.CrossRefPubMed Fawzi MH, Fawzi MM, Fawzi MM, Said NS. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res. 2011;190:91–7.CrossRefPubMed
41.
go back to reference Akanji AO, Ohaeri JU, Al-Shammri S, Fatania HR. Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Res. 2009;169:56–61.CrossRefPubMed Akanji AO, Ohaeri JU, Al-Shammri S, Fatania HR. Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Res. 2009;169:56–61.CrossRefPubMed
42.
go back to reference Sheehan D. The Mini international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic psychiatric interview. J Clin Psychiatry. 1998;59:22. Sheehan D. The Mini international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic psychiatric interview. J Clin Psychiatry. 1998;59:22.
43.
go back to reference Hicks M, Gebicki J. A spectrophotometric method for the determination of lipid hydroperoxides. Anal Biochem. 1979;99:249–53.CrossRefPubMed Hicks M, Gebicki J. A spectrophotometric method for the determination of lipid hydroperoxides. Anal Biochem. 1979;99:249–53.CrossRefPubMed
44.
go back to reference Field PA, Vasan RS. LDL-cholesterol is not the only clinically relevant biomarker for coronary artery disease or acute coronary syndrome. Clin Pharmacol Ther. 2018;104:232–4.CrossRefPubMedPubMedCentral Field PA, Vasan RS. LDL-cholesterol is not the only clinically relevant biomarker for coronary artery disease or acute coronary syndrome. Clin Pharmacol Ther. 2018;104:232–4.CrossRefPubMedPubMedCentral
45.
go back to reference Al-Hakeim HK, Al-Rammahi DA, Al-Dujaili AH. IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J Affect Disord. 2015;182:106–14.CrossRefPubMed Al-Hakeim HK, Al-Rammahi DA, Al-Dujaili AH. IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J Affect Disord. 2015;182:106–14.CrossRefPubMed
46.
go back to reference Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and nutrition examination survey, 1988-2012. Prev Chronic Dis. 2017;14:E24.CrossRefPubMedPubMedCentral Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and nutrition examination survey, 1988-2012. Prev Chronic Dis. 2017;14:E24.CrossRefPubMedPubMedCentral
47.
go back to reference Jeong SH, Lee NY, Kim SH, Chung IW, Youn T, Kang UG, et al. Long-term evolution of metabolic status in patients with schizophrenia stably maintained on second-generation antipsychotics. Psychiatry Investig. 2018;15:628–37.CrossRefPubMedPubMedCentral Jeong SH, Lee NY, Kim SH, Chung IW, Youn T, Kang UG, et al. Long-term evolution of metabolic status in patients with schizophrenia stably maintained on second-generation antipsychotics. Psychiatry Investig. 2018;15:628–37.CrossRefPubMedPubMedCentral
48.
go back to reference Kucerova J, Babinska Z, Horska K, Kotolova H. The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review. Biomed Pap Med Fac Univ Palacký, Olomouc, Czechoslov. 2015;159:208–14.CrossRef Kucerova J, Babinska Z, Horska K, Kotolova H. The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review. Biomed Pap Med Fac Univ Palacký, Olomouc, Czechoslov. 2015;159:208–14.CrossRef
49.
go back to reference Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: Baseline results from the RAISE-ETP Study. JAMA Psychiatry 2. 2014;71:1350–63.CrossRef Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: Baseline results from the RAISE-ETP Study. JAMA Psychiatry 2. 2014;71:1350–63.CrossRef
50.
go back to reference Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. Front Psych. 2014;5:137. Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. Front Psych. 2014;5:137.
51.
go back to reference Zhao S, Xia H, Mu J, Wang L, Zhu L, Wang A, et al. 10-year CVD risk in Han Chinese mainland patients with schizophrenia. Psychiatry Res. 2018;264:322–6.CrossRefPubMed Zhao S, Xia H, Mu J, Wang L, Zhu L, Wang A, et al. 10-year CVD risk in Han Chinese mainland patients with schizophrenia. Psychiatry Res. 2018;264:322–6.CrossRefPubMed
52.
go back to reference Khan IM, Pokharel Y, Dadu RT, Lewis DE, Hoogeveen RC, Wu H, et al. Postprandial monocyte activation in individuals with metabolic syndrome. J Clin Endocrinol Metab. 2016;101:4195–204.CrossRefPubMedPubMedCentral Khan IM, Pokharel Y, Dadu RT, Lewis DE, Hoogeveen RC, Wu H, et al. Postprandial monocyte activation in individuals with metabolic syndrome. J Clin Endocrinol Metab. 2016;101:4195–204.CrossRefPubMedPubMedCentral
53.
go back to reference Devaraj S, Kumaresan PR, Jialal I. C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clin Chem. 2011;57:1757–61.CrossRefPubMed Devaraj S, Kumaresan PR, Jialal I. C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clin Chem. 2011;57:1757–61.CrossRefPubMed
54.
go back to reference Scaini G, Quevedo J, Velligan D, Roberts DL, Raventos H, Walss-Bass C. Second generation antipsychotic-induced mitochondrial alterations: implications for increased risk of metaboloic syndrome in patients with schizophrenia. Eur Neuropsychopharmacol. 2018;28:369–80.CrossRefPubMed Scaini G, Quevedo J, Velligan D, Roberts DL, Raventos H, Walss-Bass C. Second generation antipsychotic-induced mitochondrial alterations: implications for increased risk of metaboloic syndrome in patients with schizophrenia. Eur Neuropsychopharmacol. 2018;28:369–80.CrossRefPubMed
55.
go back to reference Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.CrossRefPubMed Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.CrossRefPubMed
56.
go back to reference Aas M, Dieset I, Hope S, Hoseth E, Mørch R, Reponen E, et al. Childhood maltreatment severity is associated with elevated C-reactive protein and body mass index in adults with schizophrenia and bipolar diagnoses. Brain Behav Immun. 2017;65:342–9.CrossRefPubMed Aas M, Dieset I, Hope S, Hoseth E, Mørch R, Reponen E, et al. Childhood maltreatment severity is associated with elevated C-reactive protein and body mass index in adults with schizophrenia and bipolar diagnoses. Brain Behav Immun. 2017;65:342–9.CrossRefPubMed
Metadata
Title
Correlations between Body Mass Index, Plasma High-Sensitivity C-Reactive Protein and Lipids in Patients with Schizophrenia
Authors
Ted Boozalis
Sridevi Devaraj
Olaoluwa O. Okusaga
Publication date
01-03-2019
Publisher
Springer US
Published in
Psychiatric Quarterly / Issue 1/2019
Print ISSN: 0033-2720
Electronic ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-018-9606-3

Other articles of this Issue 1/2019

Psychiatric Quarterly 1/2019 Go to the issue